FDA OKs Breckenridge's ANDA for rizatriptan benzoate

01/2/2013 | Pharmaceutical Business Review Online

Breckenridge Pharmaceutical's abbreviated new-drug application for rizatriptan benzoate tablets received FDA approval. The tablet, manufactured by Natco Pharma, is the bioequivalent of Merck & Co.'s prescription migraine drug Maxalt.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC